Backstage Heroes-Yeast in COVID-19 Research

• Published in: International journal of molecular sciences 2024-12, Vol.25 (23), p.12661
• Main Authors: Grabiński, Wojciech, Karachitos, Andonis, Kicińska, Anna
• Format: Article
• Language: English
• Subjects: Analysis; Angiotensin-Converting Enzyme 2 - metabolism; Antibodies; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Artificial chromosomes; Biology; Cell cycle; Cloning; Coronavirus 3C Proteases - antagonists & inhibitors; Coronavirus 3C Proteases - metabolism; COVID-19 - immunology; COVID-19 - virology; COVID-19 vaccines; COVID-19 Vaccines - immunology; CRISPR; Drug discovery; Drug Discovery - methods; Epidemics; Evolution; Gene expression; Genetic engineering; Genomes; Glycoproteins; Health aspects; Humans; Medical research; Medicine, Experimental; Metabolism; Mutation; Pandemics; Proteases; Protein expression; Proteins; Saccharomyces cerevisiae - metabolism; SARS-CoV-2 - drug effects; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - immunology; Spike Glycoprotein, Coronavirus - metabolism; Viral antibodies; Viral antigens; Viral proteins; Virus diseases; Yeast
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms252312661

The extremely rapid development of understanding and technology that led to the containment of the COVID-19 pandemic resulted from collaborative efforts in the fields of (SARS-CoV-2) biology, pharmacology, vaccinology, and medicine. Perhaps surprisingly, much of the research was conducted using simple and efficient yeast models. In this manuscript, we describe how yeast, eukaryotic microorganisms, have been used to research this global challenge, focusing on the therapeutic potential of the studies discussed herein. Thus, we outline the role of yeast in studying viral protein interactions with the host cell proteome, including the binding of the SARS-CoV-2 virus spike protein to the human ACE2 receptor and its modulation. The production and exploration of viral antigens in yeast systems, which led to the development of two approved COVID-19 vaccines, are also detailed. Moreover, yeast platforms facilitating the discovery and production of single-domain antibodies (nanobodies) against SARS-CoV-2 are described. Methods guiding modern and efficient drug discovery are explained at length. In particular, we focus on studies designed to search for inhibitors of the main protease (Mpro), a unique target for anti-coronaviral therapies. We highlight the adaptability of the techniques used, providing opportunities for rapid modification and implementation alongside the evolution of the SARS-CoV-2 virus. Approaches introduced in yeast systems that may have universal potential application in studies of emerging viral diseases are also described.